Featured Articles

1. Unanticipated Roadblocks In Ovarian Cancer Drug Development 3/9/2026

   Ovarian cancer trials require specialized strategies that go beyond generic tumor designs. Enhance your program by enabling community referral pipelines, aligning imaging with biomarker assessments, and selecting sites based on verifiable surgical capacity.

2. Challenges That Derail Bladder Cancer Trials And How To Anticipate Them Earlier 3/5/2026

   From the rapid evolution of standard-of-care benchmarks to the logistical strain of procedure-heavy urology workflows, the path to a successful endpoint is filled with operational friction.

3. Early Phase Oncology Site Network: Benefits Of A Personal Touch 11/17/2025

   Choose a site network built on partnership — not volume — to drive smoother early-phase oncology trials and deliver better outcomes for sponsors, sites, and patients.

4. The Growing Complexity Of Conducting Oncology Trials 11/17/2025

   As diversity plans and multi-regional considerations become core to trial design, early-phase oncology programs must navigate a landscape that offers unprecedented opportunity.

5. Precision Medicine: Targeted Cancer Therapies 10/2/2025

   Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

6. Specialized Site Network For Early-Phase Oncology Success 10/2/2025

   Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

7. Working With A Specialty Oncology CRO Versus A Large Generalist CRO 10/2/2025

   Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

8. Key Takeaways From ADCs In Oncology Trials Webinar 10/2/2025

   By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

9. The Evolving Landscape Of Oncology Drug Development 9/17/2025

   Explore the novel drug modalities poised to revolutionize oncology and improve patient outcomes.

10. The Resurgence Of Antibody-Drug Conjugates 9/1/2025

    As advancements in ADC technology and clinical trial methodologies progress, Antibody-Drug Conjugates (ADCs) are poised to become pivotal in precision oncology.